The importance of early immunotherapy in patients with faciobrachial dystonic seizures
Top Cited Papers
Open Access
- 18 December 2017
- journal article
- editorial
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (2) , 348-356
Abstract
Faciobrachial dystonic seizures and limbic encephalitis closely associate with antibodies to leucine-rich glioma-inactivated 1 (LGI1). Here, we describe 103 consecutive patients with faciobrachial dystonic seizures and LGI1 antibodies to understand clinical, therapeutic and serological differences between those with and without cognitive impairment, and to determine whether cessation of faciobrachial dystonic seizures can prevent cognitive impairment. The 22/103 patients without cognitive impairment typically had normal brain MRI, EEGs and serum sodium levels (P < 0.0001). Overall, cessation of faciobrachial dystonic seizures with antiepileptic drugs alone occurred in only 9/89 (10%) patients. By contrast, 51% showed cessation of faciobrachial dystonic seizures 30 days after addition of immunotherapy (P < 0.0001), with earlier cessation in cognitively normal patients (P = 0.038). Indeed, expedited immunotherapy (P = 0.031) and normal cognition (P = 0.0014) also predicted reduced disability at 24 months. Furthermore, of 80 patients with faciobrachial dystonic seizures as their initial feature, 56% developed cognitive impairment after 90 days of active faciobrachial dystonic seizures. Whereas only one patient developed cognitive impairment after cessation of faciobrachial dystonic seizures (P < 0.0001). All patients had IgG4-LGI1 antibodies, but those with cognitive impairment had higher proportions of complement-fixing IgG1 antibodies (P = 0.03). Both subclasses caused LGI1-ADAM22 complex internalization, a potential non-inflammatory epileptogenic mechanism. In summary, faciobrachial dystonic seizures show striking time-sensitive responses to immunotherapy, and their cessation can prevent the development of cognitive impairment.Keywords
Funding Information
- Wellcome Trust (104079/Z/14/Z)
- Epilepsy Research Institute UK (P1201)
This publication has 30 references indexed in Scilit:
- LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channelsProceedings of the National Academy of Sciences, 2017
- Anti‐LGI1 encephalitis is associated with unique HLA subtypesAnnals of Neurology, 2016
- Anti-LGI1 encephalitisNeurology, 2016
- Anti-LGI1–associated cognitive impairmentNeurology, 2016
- VGKC-complex/LGI1-antibody encephalitis: Clinical manifestations and response to immunotherapyJournal of Neuroimmunology, 2013
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Faciobrachial dystonic seizures arise from cortico–subcortical abnormal brain areasJournal of Neurology, 2013
- Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsyNeurology, 2007
- Subgroup analysis in randomised controlled trials: importance, indications, and interpretationThe Lancet, 2005
- Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitisBrain, 2004